The long-pending $4-billion merger between Sun Pharmaceuticals and Ranbaxy Laboratories today...
CCI clears Sun-Ranbaxy deal with riders; asks to sell 7 brands
New Delhi, Dec 8 (PTI) Drug-makers Sun Pharma and Ranbaxy today got fair trade watchdog CCI’s approval for their long- pending USD 4-billion merger, but with a condition that they will have to modify the deal by divesting seven key products to address monopoly concerns.
The regulator, which has ordered Ranbaxy to sell six products and Sun to divest one, will also appoint a monitoring committee to oversee compliance to the conditions put forth by it to ensure that the merger does not hit competition.
The approval, which comes within days of clearance from the Foreign Investment Promotion Board (FIPB), for the deal that was announced in April and would create create India’s largest and world’s fifth biggest drug-maker.
Besides, this was the first case which the Competition Commission of India (CCI) subjected to a public scrutiny process as it had found the deal ‘prima facie’ in violation of the competition laws.
In its order dated December 5 and made public today, the CCI said it “approves the proposed combination… subject to the parties carrying out the modification to the proposed combination”.
CCI has directed Sun Pharma to divest all products containing ‘Tamsulosin + Tolterodine’ which are at present marketed and supplied under the Tamlet brand name.
Similarly, Ranbaxy would be required to divest all products containing Leuprorelin which are marketed and supplied under the Eligard brand name.
Ranbaxy would also have to divest products such as Terlibax, Rosuvas EZ, Olanex F, Raciper L and Triolvance.
According to the fair trade watchdog, the modification to the proposed deal aims “to maintain the existing level of competition in the relevant markets in India”.
The merged entity would have operations in 65 nations, 47 manufacturing facilities across 5 continents, along with a global portfolio of speciality and generic products.
CCI Chairman Ashok Chawla later said this was the Commission’s final order in the case and it was likely to appoint the monitoring agency in the next few days to oversee compliance to the directions.
As per the order, Sun Pharma and Ranbaxy have six months to divest or procure the divestiture of divestment products.
“The divestiture shall not be given effect to unless and until the Commission has approved the terms of final and binding sale and purchase agreement(s) and the purchaser(s) proposed by the parties,” the order said.
“The proposed combination shall not be effected by the parties until approved sale and purchase agreement(s) have been entered into in accordance with the order,” it added.
CCI also asked the two firms to give full information regarding divestment products to potential purchasers so as to enable them to undertake reasonable due diligence.
“The parties may require the potential purchasers to execute a confidentiality agreement before providing access to information regarding the divestment product(s),” CCI said.
Further, CCI would appoint a monitoring agency to “monitor the due diligence process, including the preparation of data room documentation, in accordance with the monitoring agency agreement”.
Sun and Ranbaxy are each required to appoint a senior management level employee within seven days who would under the supervision of the monitoring agency ensure that the economic viability, marketability and competitiveness of the divestment products are maintained till the closing date.
As per the Commission’s order divestment would not include any manufacturing facilities of the two companies, intellectual property rights which do not contribute to the current operations as well as general books of account and books of original entry that comprise the parties permanent accounting or tax records.
In April, Sun Pharmaceutical Industries announced it would acquire troubled rival Ranbaxy Laboratories in a USD 4-billion deal that includes USD 800 million debt. The transaction has valued Ranbaxy at 2.2 times its USD 1.8 billion revenue for 2013, or about Rs 457 per share.
Sun Pharma, Ranbaxy agree to sell 7 products to meet CCI conditions
Asked by CCI to divest seven products, drug makers Sun Pharmaceutical and Ranbaxy today said they will comply with the conditions put forth by the fair trade regulator to take forward their proposed merger.
While approving their USD 4-billion merger, Competition Commission of India (CCI) has asked the two companies to divest seven products to address anti-competitive concerns.
“Sun Pharma and Ranbaxy are looking forward to progressing towards the completion of the transaction and will comply with the conditions laid down by the CCI within the specified time,” the two firms said in a joint statement.
They also added that these products constitute less than one per cent of the combined entity’s revenues in India. The divestment needs to be finalised within six months.
The two companies announced their merger in April this year and the merged entity is expected to be India’s largest and the world’s fifth largest drug maker with combined revenue of USD 4.2 billion.
In their joint statement, the two firms said they have received the CCI order where acquisition of Ranbaxy by Sun Pharma has been approved “subject to compliance with certain conditions”.
“Over the past few months, the CCI has sought information and detailed clarifications for the purposes of making its assessment. One of the preconditions of the order is that parties procure the divestment of seven products,” they added.
Terming the CCI approval as a major milestone for the deal, Sun Pharma MD Dilip Shanghvi said: “It revalidates our view that the Sun Pharma and Ranbaxy businesses complement each other with limited product overlap, and will offer a comprehensive product basket to enable future growth.
Ranbaxy CEO Arun Sawhney said, “We are confident that post closure, the combined entity will enable sustainable long term growth and deliver immense value for all stakeholders.”
Established in 1983, Sun Pharmaceutical Industries has emerged as a major speciality pharmaceutical company with over 75 per cent sales from global markets, while it has expanded its business mostly through acquisitions.
For the year ending March 2014, its overall revenues were at USD 2.7 billion, of which the US contributed USD 1.6 billion.
Ranbaxy was also a home-grown company, but its then promoters, Malvinder Mohan Singh and Shivinder Mohan Singh, sold the majority stake in the company to Japan’s Daiichi Sankyo in 2008. In April this year, Ranbaxy reached a deal for its merger with Sun Pharma.
Ranbaxy has been going through frequent regulatory run-ins with overseas health watchdogs including in the US and Europe.